PHO-COG-FALLON-ACNS0332; Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotrectinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
The overall goal of this study is to compare the effects, good and/or bad, of the chemotherapy drugs carboplatin and isotretinoin on subjects with high risk medulloblastoma and to find out if one or both are better than standard therapy alone.
The purpose of this study is to determine whether carboplatin radiosensitization increases long term event-free survival for high risk medulloblastoma/primitive neuroectodermal tumor (PNET) patients and to determine whether isotretinoin increases long term event-free survival for high risk medulloblastoma/PNET patients.
- IRB Number: 1106005984 (0707-01)
- Research Study Identifier: TX481
- Principal Investigator: Kamnesh Pradhan, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required